Sign In
Buy CAR
$137.44
-14.56 (-9.58%)
At Close: Jul 31, 2026
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS
07:15am, Monday, 06'th Jul 2026
Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory align
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
10:10am, Saturday, 04'th Jul 2026
Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in
Strong Car Rental Demand Aids Avis Budget Group Amid Low Liquidity
10:36am, Friday, 03'rd Jul 2026
CAR gains from rising demand for short-term vehicle rentals, but geopolitical risks, low liquidity and lack of dividend cloud its long-term outlook.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
10:35am, Monday, 29'th Jun 2026
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if s
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants Ovarian cancer CAR-T therapy, l
Avis Wins $650 Million From Hedge Fund That Bet Big on Its Stock
08:37am, Tuesday, 23'rd Jun 2026
Pentwater Capital agrees to pay Avis Budget after it was accused of fueling excess volatility in the car-rental company's stock.
Reasons Why You Should Retain Avis Budget Stock in Your Portfolio
12:41pm, Monday, 15'th Jun 2026
CAR shares jump 28% in a month as pricing improves, fleet utilization hits a 15-year high and earnings are projected to surge in 2026.
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependen
BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data f
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
12:23pm, Saturday, 13'th Jun 2026
Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL. LYLE trades near cash value, with the market heavily discoun
These 10 Stocks Are Getting Crushed By Short Sellers Right Now
06:17pm, Thursday, 11'th Jun 2026
Short sellers are piling into a wide-ranging group of names, with the latest Benzinga Pro data showing elevated bearish positioning across 10 stocks with short interest ranging from 37% to 87%.
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
06:06am, Tuesday, 09'th Jun 2026
Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-
Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported stron
